← Leaderboards
Kenneth C Anderson
Dana-Farber Cancer Inst
$25,995,373
Attributed
$29,311,661
Total exposure
22
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$100,523,952 · 24
By mechanism
P50$57,806,810 · 13
P01$33,906,428 · 8
R01$8,810,714 · 3
Top collaborators
- Constantine S. Mitsiades10 shared
- Dharminder Chauhan5 shared
- Teru Hideshima5 shared
- Nikhil C. Munshi5 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- James E Bradner$6,722,003
- Teru Hideshima$1,761,647
- Irene M. Ghobrial$24,445,801
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Multiple MyelomaFundingClinical TrialsBone MarrowCellsProgramsDrug ResistanceMolecularIn VitroClinical ResearchBench To BedsideNeoplastic CellResearch PersonnelBaseTranslatingIn VivoPre-ClinicalIn Vivo ModelInstitutionTranslationsNovel TherapeuticsDana-Farber Cancer InstituteTherapeutic TargetCell Growth
Grant awards (151)
Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma$259,300
P01 · FY2025 · CA · contact PI
Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma$240,658
P01 · FY2024 · CA · contact PI
SPORE in Multiple Myeloma$2,257,199
P50 · FY2023 · CA · contact PI
Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma$405,145
P50 · FY2023 · CA · contact PI
Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma$313,545
P01 · FY2023 · CA · contact PI
Administration, Communication and Planning$283,191
P50 · FY2023 · CA · contact PI
Developmental Research Program$165,540
P50 · FY2023 · CA · contact PI
Career Enhancement Program$165,540
P50 · FY2023 · CA · contact PI
SPORE in Multiple Myeloma$2,257,199
P50 · FY2022 · CA · contact PI
Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma$405,145
P50 · FY2022 · CA · contact PI
Administration, Communication and Planning$283,192
P50 · FY2022 · CA · contact PI
Career Enhancement Program$165,539
P50 · FY2022 · CA · contact PI
Developmental Research Program$165,537
P50 · FY2022 · CA · contact PI
SPORE in Multiple Myeloma$2,257,199
P50 · FY2021 · CA · contact PI
Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma$477,256
P50 · FY2021 · CA · contact PI
Administration, Communication and Planning$304,504
P50 · FY2021 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$280,604
P01 · FY2021 · CA · contact PI
Developmental Research Program$102,873
P50 · FY2021 · CA · contact PI
SPORE in Multiple Myeloma$2,349,611
P50 · FY2020 · CA · contact PI
Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma$425,955
P50 · FY2020 · CA · contact PI
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma$395,166
R01 · FY2020 · CA · contact PI
Administration, Communication and Planning$294,819
P50 · FY2020 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$280,604
P01 · FY2020 · CA · contact PI
Developmental Research Program$168,314
P50 · FY2020 · CA · contact PI
Career Enhancement Program$168,314
P50 · FY2020 · CA · contact PI
SPORE in Multiple Myeloma$2,276,698
P50 · FY2019 · CA · contact PI
Therapeutically Targeting Ubiquitin Receptors in Multiple Myeloma$405,145
P50 · FY2019 · CA · contact PI
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma$383,310
R01 · FY2019 · CA · contact PI
Administration, Communication and Planning$283,189
P50 · FY2019 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$280,606
P01 · FY2019 · CA · contact PI
Developmental Research Program$165,540
P50 · FY2019 · CA · contact PI
Career Enhancement Program$165,540
P50 · FY2019 · CA · contact PI
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma$395,166
R01 · FY2018 · CA · contact PI
Functional and biologic significance of deacetylase3 inhibition in myeloma$353,291
R01 · FY2018 · CA
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2018 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$280,604
P01 · FY2018 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$29,416
P01 · FY2018 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$9,805
P01 · FY2018 · CA · contact PI
SPORE in Multple Myeloma$2,300,000
P50 · FY2017 · CA · contact PI
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma$395,166
R01 · FY2017 · CA · contact PI
Functional and biologic significance of deacetylase3 inhibition in myeloma$353,291
R01 · FY2017 · CA
Targeting Deubiquitylating Enzymes in Multiple Myeloma$324,985
P50 · FY2017 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2017 · CA · contact PI
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma$283,488
P01 · FY2017 · CA · contact PI
Administration, Communication, and Planning Core$261,609
P50 · FY2017 · CA · contact PI
Developmental Research Program$156,981
P50 · FY2017 · CA · contact PI
Career Development Program$156,981
P50 · FY2017 · CA · contact PI
SPORE in Multple Myeloma$2,162,000
P50 · FY2016 · CA · contact PI
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma$395,166
R01 · FY2016 · CA · contact PI
Functional and biologic significance of deacetylase3 inhibition in myeloma$353,291
R01 · FY2016 · CA
Targeting Deubiquitylating Enzymes in Multiple Myeloma$302,224
P50 · FY2016 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2016 · CA · contact PI
Administration, Communication, and Planning Core$245,628
P50 · FY2016 · CA · contact PI
Career Development Program$152,194
P50 · FY2016 · CA · contact PI
Developmental Research Program$152,194
P50 · FY2016 · CA · contact PI
SPORE in Multple Myeloma$2,185,000
P50 · FY2015 · CA · contact PI
Functional and biologic significance of deacetylase3 inhibition in myeloma$353,291
R01 · FY2015 · CA
Targeting Deubiquitylating Enzymes in Multiple Myeloma$305,438
P50 · FY2015 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2015 · CA · contact PI
Administration, Communication, and Planning Core$248,240
P50 · FY2015 · CA · contact PI
Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom$213,234
P01 · FY2015 · CA · contact PI
Career Development Program$153,814
P50 · FY2015 · CA · contact PI
Developmental Research Program$153,814
P50 · FY2015 · CA · contact PI
SPORE in Multple Myeloma$2,162,001
P50 · FY2014 · CA · contact PI
Host-tumor cell interaction in myeloma: therapeutic applications$1,885,301
P01 · FY2014 · CA · contact PI
Functional and biologic significance of deacetylase3 inhibition in myeloma$353,291
R01 · FY2014 · CA
Targeting Myeloma Cell-Host Bone Marrow Interactions$342,342
P01 · FY2014 · CA · contact PI
Targeting Deubiquitylating Enzymes in Multiple Myeloma$301,819
P50 · FY2014 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$301,545
R01 · FY2014 · CA · contact PI
Administrative and Clinical Support$301,254
P01 · FY2014 · CA · contact PI
Administration, Communication, and Planning Core$245,680
P50 · FY2014 · CA · contact PI
Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom$207,345
P01 · FY2014 · CA · contact PI
Career Development Program$152,228
P50 · FY2014 · CA · contact PI
Developmental Research Program$152,228
P50 · FY2014 · CA · contact PI
SPORE in Multple Myeloma$2,150,500
P50 · FY2013 · CA · contact PI
Host-tumor cell interaction in myeloma: therapeutic applications$1,841,280
P01 · FY2013 · CA · contact PI
Targeting Myeloma Cell-Host Bone Marrow Interactions$320,730
P01 · FY2013 · CA · contact PI
Administrative and Clinical Support$300,629
P01 · FY2013 · CA · contact PI
Targeting Deubiquitylating Enzymes in Multiple Myeloma$298,004
P50 · FY2013 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$262,054
R01 · FY2013 · CA · contact PI
Administration, Communication, and Planning Core$242,200
P50 · FY2013 · CA · contact PI
Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom$200,984
P01 · FY2013 · CA · contact PI
Developmental Research Program$150,072
P50 · FY2013 · CA · contact PI
Career Development Program$150,072
P50 · FY2013 · CA · contact PI
SPORE in Myeloma$2,300,000
P50 · FY2012 · CA · contact PI
Host-tumor cell interaction in myeloma: therapeutic applications$1,974,463
P01 · FY2012 · CA · contact PI
Targeting Myeloma Cell-Host Bone Marrow Interactions$361,613
P01 · FY2012 · CA · contact PI
Administrative and Clinical Support$314,661
P01 · FY2012 · CA · contact PI
P-1: Proteosome-directed novel myeloma therapies$285,079
P50 · FY2012 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$278,781
R01 · FY2012 · CA · contact PI
Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom$214,833
P01 · FY2012 · CA · contact PI
CA: Administration Core$200,068
P50 · FY2012 · CA · contact PI
Developmental Research Program$129,410
P50 · FY2012 · CA · contact PI
Career Development Program$129,409
P50 · FY2012 · CA · contact PI
SPORE in Myeloma$2,185,000
P50 · FY2011 · CA · contact PI
Host-tumor cell interaction in myeloma: therapeutic applications$1,984,614
P01 · FY2011 · CA · contact PI
Targeting Myeloma Cell-Host Bone Marrow Interactions$363,778
P01 · FY2011 · CA · contact PI
Administrative and Clinical Support$316,013
P01 · FY2011 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$278,781
R01 · FY2011 · CA · contact PI
P-1: Proteosome-directed novel myeloma therapies$273,841
P50 · FY2011 · CA · contact PI
Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom$263,055
P01 · FY2011 · CA · contact PI
CA: Administration Core$191,065
P50 · FY2011 · CA · contact PI
Career Development Program$123,586
P50 · FY2011 · CA · contact PI
Developmental Research Program$123,584
P50 · FY2011 · CA · contact PI
SPORE in Myeloma$2,300,000
P50 · FY2010 · CA · contact PI
Host-tumor cell interaction in myeloma: therapeutic applications$2,056,275
P01 · FY2010 · CA · contact PI
Targeting Myeloma Cell-Host Bone Marrow Interactions$1,025,504
P01 · FY2010 · CA · contact PI
P-1: Proteosome-directed novel myeloma therapies$289,159
P50 · FY2010 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$287,403
R01 · FY2010 · CA · contact PI
CA: Administration Core$200,548
P50 · FY2010 · CA · contact PI
Administrative and Clinical Support$197,397
P01 · FY2010 · CA · contact PI
Career Development Program$129,720
P50 · FY2010 · CA · contact PI
Developmental Research Program$129,719
P50 · FY2010 · CA · contact PI
SPORE in Myeloma$2,300,000
P50 · FY2009 · CA · contact PI
Host-Tumor Cell Interactions in Myeloma: Therapeutic Applications$514,934
P01 · FY2009 · CA · contact PI
P-1: Proteosome-directed novel myeloma therapies$289,920
P50 · FY2009 · CA · contact PI
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications$287,403
R01 · FY2009 · CA · contact PI
CA: Administration Core$199,847
P50 · FY2009 · CA · contact PI
SPORE in Myeloma$172,667
P50 · FY2009 · CA · contact PI
Career Development Program$129,266
P50 · FY2009 · CA · contact PI
Developmental Research Program$129,265
P50 · FY2009 · CA · contact PI
SPORE in Myeloma$2,300,000
P50 · FY2008 · CA · contact PI
Host-Tumor Cell Interactions in Myeloma:$1,346,410
P01 · FY2008 · CA · contact PI
P-1: Proteosome-directed novel myeloma therapies$211,763
P50 · FY2008 · CA · contact PI
CA: Administration Core$145,058
P50 · FY2008 · CA · contact PI
Career Development Program$93,827
P50 · FY2008 · CA · contact PI
Developmental Research Program$93,827
P50 · FY2008 · CA · contact PI
Specialized Program of Research Excellence in Myeloma$2,136,145
P50 · FY2007 · CA · contact PI
Host-Tumor Cell Interactions in Myeloma: Therapeutic Applications$2,008,736
P01 · FY2007 · CA · contact PI
Role of Cytokines in Myeloma Pathogenesis$283,743
R01 · FY2007 · CA · contact PI
Specialized Program of Research Excellence in Myeloma$2,199,943
P50 · FY2006 · CA · contact PI
Host-Tumor Cell Interactions in Myeloma:$2,020,671
P01 · FY2006 · CA · contact PI
Role of Cytokines in Myeloma Pathogenesis$292,218
R01 · FY2006 · CA · contact PI
Specialized Program of Research Excellence in Myeloma$2,252,886
P50 · FY2005 · CA
Host-Tumor Cell Interactions in Myeloma:$2,021,516
P01 · FY2005 · CA
Role of Cytokines in Myeloma Pathogenesis$299,250
R01 · FY2005 · CA
Specialized Program of Research Excellence in Myeloma$2,248,118
P50 · FY2004 · CA
Host-Tumor Cell Interactions in Myeloma:$1,974,474
P01 · FY2004 · CA
Role of Cytokines in Myeloma Pathogenesis$299,250
R01 · FY2004 · CA
Specialized Program of Research Excellence in Myeloma$2,250,000
P50 · FY2003 · CA
Host-Tumor Cell Interactions in Myeloma Therapeutic Appl$1,917,010
P01 · FY2003 · CA
Role of Cytokines in Myeloma Pathogenesis$299,250
R01 · FY2003 · CA
NOVEL IMMUNE BASED THERAPIES FOR MULTIPLE MYELOMA$1,538,491
P01 · FY2002 · CA
KSHV AND VIL6 IN THE PATHOGENESIS OF MULTIPLE MYELOMA$240,080
R01 · FY2002 · CA
ALLOGENEIC GRAFT-VS-MYELOMA IMMUNITY AFTER STEM CELL TRANSPLANTATION$109,507
P01 · FY2002 · CA
NOVEL IMMUNE BASED THERAPIES FOR MULTIPLE MYELOMA$1,503,053
P01 · FY2001 · CA
KSHV AND VIL6 IN THE PATHOGENESIS OF MULTIPLE MYELOMA$234,758
R01 · FY2001 · CA
ALLOGENEIC GRAFT-VS-MYELOMA IMMUNITY AFTER STEM CELL TRANSPLANTATION$109,507
P01 · FY2001 · CA
NOVEL IMMUNE BASED THERAPIES FOR MULTIPLE MYELOMA$1,622,897
P01 · FY2000 · CA
ALLOGENEIC GRAFT-VS-MYELOMA IMMUNITY AFTER STEM CELL TRANSPLANTATION$275,287
P01 · FY2000 · CA
KSHV AND VIL6 IN THE PATHOGENESIS OF MULTIPLE MYELOMA$229,589
R01 · FY2000 · CA